Clinical rheumatology · 2025
Integration of metabolomics and genomics implicates a causality between 1398 blood metabolites and gout.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fan Mingyuan, Yun Zhangjun, Yuan Jiushu, Lu Dingyi, Xie Hongyan, Yuan Haipo, Gao Hong
Аннотация
INTRODUCTION: Metabolic disorders represent a hallmark feature of gout. However, evidence on the causality of blood metabolites and gout remains lacking. We performed a Mendelian randomization (MR) analysis to systematically evaluate the causality from genetically proxied 1398 blood metabolites to gout.
METHOD: Genome-wide association study (GWAS) data for 1398 blood metabolites were extracted from 8299 European subjects. The discovery stage was performed using gout data from FinnGen consortium R9 to initially explore causal associations between metabolites and gout. The significant associations identified in the discovery stage were validated in the replication stage employing gout GWAS data from the IEU database. Random-effect inverse variance weighted was chosen as the main method for causality analysis, with MR-Egger, weighted median, robust adjusted profile score, and maximum likelihood as complementary analysis methods. Then, a series of sensitivity analyses were performed.
RESULTS: Results showed that there was a significant causal relationship between eight metabolites and gout, including 21-hydroxypregnenolone disulfate levels, carnitine levels, ethyl beta-glucopyranoside levels, gamma-glutamylglycine levels, glycine levels, glycine-to-alanine ratio, glycolithocholate sulfate levels, and propionylglycine levels. Colocalization analysis evidence strongly supported a causal relationship between 21-hydroxypregnenolone disulfate levels and carnitine levels and gout. In addition, four metabolic pathways were involved in the biological process of gout (carnitine synthesis, beta oxidation of very long-chain fatty acids, alanine metabolism, glutathione metabolism).
CONCLUSIONS: The current study provides evidentiary support for the causal relationship between eight blood metabolites and gout and identifies four significant metabolic pathways. These findings hold the potential to inform future research, clinical interventions, and therapeutic strategies for gout.
METHOD: Genome-wide association study (GWAS) data for 1398 blood metabolites were extracted from 8299 European subjects. The discovery stage was performed using gout data from FinnGen consortium R9 to initially explore causal associations between metabolites and gout. The significant associations identified in the discovery stage were validated in the replication stage employing gout GWAS data from the IEU database. Random-effect inverse variance weighted was chosen as the main method for causality analysis, with MR-Egger, weighted median, robust adjusted profile score, and maximum likelihood as complementary analysis methods. Then, a series of sensitivity analyses were performed.
RESULTS: Results showed that there was a significant causal relationship between eight metabolites and gout, including 21-hydroxypregnenolone disulfate levels, carnitine levels, ethyl beta-glucopyranoside levels, gamma-glutamylglycine levels, glycine levels, glycine-to-alanine ratio, glycolithocholate sulfate levels, and propionylglycine levels. Colocalization analysis evidence strongly supported a causal relationship between 21-hydroxypregnenolone disulfate levels and carnitine levels and gout. In addition, four metabolic pathways were involved in the biological process of gout (carnitine synthesis, beta oxidation of very long-chain fatty acids, alanine metabolism, glutathione metabolism).
CONCLUSIONS: The current study provides evidentiary support for the causal relationship between eight blood metabolites and gout and identifies four significant metabolic pathways. These findings hold the potential to inform future research, clinical interventions, and therapeutic strategies for gout.